BRPI0508425A - análogos de fosfolipìdeo como agentes diapêuticas e seus métodos - Google Patents
análogos de fosfolipìdeo como agentes diapêuticas e seus métodosInfo
- Publication number
- BRPI0508425A BRPI0508425A BRPI0508425-3A BRPI0508425A BRPI0508425A BR PI0508425 A BRPI0508425 A BR PI0508425A BR PI0508425 A BRPI0508425 A BR PI0508425A BR PI0508425 A BRPI0508425 A BR PI0508425A
- Authority
- BR
- Brazil
- Prior art keywords
- agents
- diaperutic
- methods
- phospholipid analogues
- phospholipid
- Prior art date
Links
- 150000003904 phospholipids Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 phospholipid ether analogs Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0408—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
ANáLOGOS DE FOSFOLIPìDEO COMO AGENTES DIAPêUTICAS E SEUS MéTODOS. A presente invenção refere-se a métodos e usos de análogos de éter de fosfolipídeo como agentes de diagnóstico e terapêuticos para vários cânceres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52116604P | 2004-03-02 | 2004-03-02 | |
PCT/US2005/006681 WO2005084716A2 (en) | 2004-03-02 | 2005-03-02 | Phospholipid analogs for diagnosis and treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0508425A true BRPI0508425A (pt) | 2007-07-24 |
Family
ID=34919310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508425-3A BRPI0508425A (pt) | 2004-03-02 | 2005-03-02 | análogos de fosfolipìdeo como agentes diapêuticas e seus métodos |
Country Status (17)
Country | Link |
---|---|
US (3) | US8535641B2 (pt) |
EP (3) | EP2044961B1 (pt) |
JP (7) | JP2007528374A (pt) |
KR (1) | KR20070015518A (pt) |
CN (1) | CN1929869B (pt) |
AT (1) | ATE437657T1 (pt) |
AU (1) | AU2005219412A1 (pt) |
BR (1) | BRPI0508425A (pt) |
CA (1) | CA2557698A1 (pt) |
DE (1) | DE602005015687D1 (pt) |
DK (1) | DK1729824T3 (pt) |
ES (3) | ES2330951T3 (pt) |
HK (1) | HK1130186A1 (pt) |
IL (1) | IL177645A0 (pt) |
MX (1) | MXPA06009681A (pt) |
WO (1) | WO2005084716A2 (pt) |
ZA (1) | ZA200607042B (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006014589A2 (en) * | 2004-07-08 | 2006-02-09 | Cellectar, Llc | Virtual colonoscopy with radiolabeled phospholipid ether analogs |
KR20070015518A (ko) * | 2004-03-02 | 2007-02-05 | 셀렉타, 엘엘씨 | 암의 진단 및 치료를 위한 포스포리피드 유사체 |
US8540968B2 (en) | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
CA2591907A1 (en) * | 2004-12-20 | 2007-02-01 | Cellectar, Llc | Phospholipid ether analogs for detecting and treating cancer |
WO2009005509A1 (en) * | 2006-08-15 | 2009-01-08 | Cellectar, Inc. | Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications |
US7893286B2 (en) | 2007-06-01 | 2011-02-22 | Cellectar, Inc. | Method for the synthesis of phospholipid ethers |
WO2008150439A1 (en) | 2007-06-01 | 2008-12-11 | Cellectar, Inc. | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use |
WO2010011844A1 (en) * | 2008-07-25 | 2010-01-28 | Tufts Medical Center | A system and method of clinical treatment planning of complex, monte carlo-based brachytherapy dose distributions |
ES2549459T3 (es) | 2009-05-11 | 2015-10-28 | Cellectar, Inc. | Compuestos de éter de fosfolípido fluorescentes, composiciones y procedimientos de uso |
US7811548B1 (en) | 2009-05-11 | 2010-10-12 | Cellectar, Inc. | Fluorescent phospholipid ether compounds and compositions |
US8871181B2 (en) | 2009-05-11 | 2014-10-28 | Cellectar, Inc. | Fluorescent phospholipid ether compounds, compositions, and methods of use |
DK2440253T3 (da) * | 2009-06-12 | 2020-07-20 | Cellectar Inc | Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller |
US10007961B2 (en) * | 2009-09-09 | 2018-06-26 | Wisconsin Alumni Research Foundation | Treatment planning system for radiopharmaceuticals |
JP2013504590A (ja) * | 2009-09-11 | 2013-02-07 | セレクター,インコーポレイティド | 非放射性リン脂質化合物、組成物、及び使用方法 |
WO2016081203A2 (en) | 2014-11-17 | 2016-05-26 | Cellectar Biosciences, Inc. | Phospholipid ether analogs as cancer-targeting drug vehicles |
US10265398B2 (en) | 2015-11-06 | 2019-04-23 | Wisconsin Alumni Research Foundation | Long-lived gadolinium based tumor targeted imaging and therapy agents |
US11467159B2 (en) * | 2016-06-14 | 2022-10-11 | Cellectar Biosciences, Inc. | Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells |
US11147823B2 (en) * | 2016-07-13 | 2021-10-19 | Wisconsin Alumni Research Foundation | Phospholipid ether analogs for imaging and targeted treatment of pediatric solid tumors |
AU2017300361B2 (en) | 2016-07-18 | 2024-08-01 | Wisconsin Alumni Research Foundation | Radiohalogenated agents for In Situ Immune Modulated Cancer Vaccination |
US11633506B2 (en) * | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
CA3031776C (en) * | 2016-07-25 | 2024-02-20 | Wisconsin Alumni Research Foundation | Targeted radiotherapy chelates for in situ immune modulated cancer vaccination |
WO2018022125A1 (en) * | 2016-07-25 | 2018-02-01 | Wisconsin Alumni Research Foundation | Radioactive phospholipid metal chelates for cancer imaging and therapy |
WO2018148224A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Car t細胞療法のための組成物および方法 |
EP3706808A1 (en) * | 2017-11-10 | 2020-09-16 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies |
US20190184040A1 (en) * | 2017-12-15 | 2019-06-20 | Wisconsin Alumni Research Foundation | Targeted Macrocyclic Agents for Dual Modality PET and MRI Imaging of Cancer |
CN112055595A (zh) | 2018-01-22 | 2020-12-08 | 恩多塞特公司 | Car t细胞的使用方法 |
WO2019156795A1 (en) * | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
KR20220080139A (ko) * | 2019-10-10 | 2022-06-14 | 셀렉타 바이오사이언시스, 인코퍼레이티드 | 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851526A (en) * | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
US4873075A (en) * | 1985-09-10 | 1989-10-10 | The University Of Michigan | Polyiodinated triglyceride analogs as radiologic agents |
US5093042A (en) * | 1985-09-10 | 1992-03-03 | The University Of Michigan | Polyiodinated triglyceride analogs as radiologic agents |
US4957729A (en) * | 1985-09-10 | 1990-09-18 | The University Of Michigan | Polyiodinated triglyceride analogs as radiologic agents |
US4925649A (en) | 1987-06-12 | 1990-05-15 | The University Of Michigan | Radioiodinated diacylglycerol analogues and methods of use |
US5087721A (en) * | 1987-10-23 | 1992-02-11 | The University Of Michigan | Radioiodinated phosphate esters |
US4965391A (en) | 1987-10-23 | 1990-10-23 | The University Of Michigan | Radioiodinated phospholipid ether analogues |
US5347030A (en) * | 1987-10-23 | 1994-09-13 | The Board Of Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogues and methods of using same |
US5041859A (en) * | 1988-10-04 | 1991-08-20 | Nikon Corporation | Automatic focusing detection device for cameras |
US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
US5369097A (en) | 1991-04-25 | 1994-11-29 | The University Of British Columbia | Phosphonates as anti-cancer agents |
US5783170A (en) * | 1991-11-27 | 1998-07-21 | Diatide, Inc. | Peptide-metal chelate conjugates |
US5626654A (en) | 1995-12-05 | 1997-05-06 | Xerox Corporation | Ink compositions containing liposomes |
US6255519B1 (en) | 1996-12-04 | 2001-07-03 | Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogs and methods of using the same |
CA2276284C (en) | 1996-12-04 | 2006-10-10 | The Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogs and methods of using the same |
US6503478B2 (en) | 1999-01-13 | 2003-01-07 | Lightouch Medical, Inc. | Chemically specific imaging of tissue |
ATE404217T1 (de) * | 1999-06-24 | 2008-08-15 | Univ British Columbia | Therapie mit lipoproteinlipase (lpl) variant |
EP1346041B1 (en) * | 2000-11-27 | 2007-02-28 | Praecis Pharmaceuticals Incorporated | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
JP4247110B2 (ja) * | 2001-06-06 | 2009-04-02 | ブルックヘブン サイエンス アソシエーツ | 新規メタロポルフィリン及び放射線治療用放射線増感剤としてのそれらの使用 |
US7220539B1 (en) | 2002-06-12 | 2007-05-22 | The Salk Institute For Biological Studies | Protein kinase B/Akt modulators and methods for the use thereof |
CA2489469C (en) * | 2002-06-14 | 2016-03-22 | Immunomedics, Inc. | Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer |
CA2492878A1 (en) * | 2002-07-19 | 2004-01-29 | Ludwig Institute For Cancer Research | Enhancing the effect of radioimmunotherapy in the treatment of tumors |
WO2005028681A1 (en) | 2003-09-19 | 2005-03-31 | Arcturus Bioscience, Inc. | Predicting breast cancer treatment outcome |
WO2005063774A1 (en) | 2003-12-22 | 2005-07-14 | Johns Hopkins University | Boronic acid aryl analogs |
US7632644B2 (en) | 2004-03-02 | 2009-12-15 | Cellectar, Inc. | Imaging and selective retention of phospholipid ether analogs |
KR20070015518A (ko) | 2004-03-02 | 2007-02-05 | 셀렉타, 엘엘씨 | 암의 진단 및 치료를 위한 포스포리피드 유사체 |
US8540968B2 (en) | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
WO2006014589A2 (en) * | 2004-07-08 | 2006-02-09 | Cellectar, Llc | Virtual colonoscopy with radiolabeled phospholipid ether analogs |
EP1729790A4 (en) | 2004-03-29 | 2009-09-30 | Robin Polt | AMPHIPATHIC GLYCOPEPTIDES |
US20060115426A1 (en) | 2004-08-11 | 2006-06-01 | Weichert Jamey P | Methods of detecting breast cancer, brain cancer, and pancreatic cancer |
US7041859B1 (en) | 2004-09-09 | 2006-05-09 | University Of Tennessee Research Foundation | Method for halogenating or radiohalogenating a chemical compound |
CA2591907A1 (en) * | 2004-12-20 | 2007-02-01 | Cellectar, Llc | Phospholipid ether analogs for detecting and treating cancer |
WO2009005509A1 (en) | 2006-08-15 | 2009-01-08 | Cellectar, Inc. | Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications |
WO2008150439A1 (en) * | 2007-06-01 | 2008-12-11 | Cellectar, Inc. | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use |
US7893286B2 (en) | 2007-06-01 | 2011-02-22 | Cellectar, Inc. | Method for the synthesis of phospholipid ethers |
GB0819280D0 (en) | 2008-10-21 | 2008-11-26 | Gen Electric | Imgaing and radiotherapy methods |
DK2440253T3 (da) | 2009-06-12 | 2020-07-20 | Cellectar Inc | Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller |
WO2011031911A1 (en) | 2009-09-11 | 2011-03-17 | Cellectar, Inc. | Deuterated alkyl phospholipid compounds, compositions, and methods of use |
JP2013504590A (ja) | 2009-09-11 | 2013-02-07 | セレクター,インコーポレイティド | 非放射性リン脂質化合物、組成物、及び使用方法 |
-
2005
- 2005-03-02 KR KR1020067018488A patent/KR20070015518A/ko not_active Application Discontinuation
- 2005-03-02 US US10/906,687 patent/US8535641B2/en active Active
- 2005-03-02 JP JP2007501917A patent/JP2007528374A/ja not_active Withdrawn
- 2005-03-02 DE DE602005015687T patent/DE602005015687D1/de active Active
- 2005-03-02 CA CA002557698A patent/CA2557698A1/en not_active Abandoned
- 2005-03-02 ES ES05729873T patent/ES2330951T3/es active Active
- 2005-03-02 MX MXPA06009681A patent/MXPA06009681A/es active IP Right Grant
- 2005-03-02 EP EP08020805.1A patent/EP2044961B1/en active Active
- 2005-03-02 AU AU2005219412A patent/AU2005219412A1/en not_active Abandoned
- 2005-03-02 EP EP08010321.1A patent/EP2044960B1/en active Active
- 2005-03-02 ES ES08010321.1T patent/ES2440257T3/es active Active
- 2005-03-02 WO PCT/US2005/006681 patent/WO2005084716A2/en active Application Filing
- 2005-03-02 ES ES08020805T patent/ES2430065T3/es active Active
- 2005-03-02 DK DK05729873T patent/DK1729824T3/da active
- 2005-03-02 CN CN2005800070569A patent/CN1929869B/zh active Active
- 2005-03-02 BR BRPI0508425-3A patent/BRPI0508425A/pt not_active Application Discontinuation
- 2005-03-02 EP EP05729873A patent/EP1729824B1/en active Active
- 2005-03-02 AT AT05729873T patent/ATE437657T1/de not_active IP Right Cessation
-
2006
- 2006-08-22 IL IL177645A patent/IL177645A0/en unknown
- 2006-08-23 ZA ZA200607042A patent/ZA200607042B/en unknown
-
2009
- 2009-09-30 HK HK09109089.4A patent/HK1130186A1/xx unknown
-
2012
- 2012-01-13 JP JP2012005213A patent/JP2012097113A/ja not_active Withdrawn
- 2012-10-24 JP JP2012234608A patent/JP2013040201A/ja active Pending
-
2013
- 2013-08-12 US US13/964,315 patent/US8877159B2/en active Active
-
2014
- 2014-07-18 JP JP2014147869A patent/JP6228080B2/ja active Active
- 2014-09-30 US US14/501,373 patent/US9550002B2/en active Active
-
2015
- 2015-01-05 JP JP2015000135A patent/JP6342818B2/ja active Active
-
2016
- 2016-07-08 JP JP2016135920A patent/JP6453818B2/ja active Active
-
2017
- 2017-05-31 JP JP2017108141A patent/JP2017173339A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508425A (pt) | análogos de fosfolipìdeo como agentes diapêuticas e seus métodos | |
CR8919A (es) | Analogos de tetrapeptidos | |
CL2011003346A1 (es) | Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente. | |
BRPI0607728A2 (pt) | complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado | |
CR11017A (es) | Anticuerpos anti-robo4 y sus usos | |
ITMI20052171A1 (it) | Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso | |
BR112013003248A2 (pt) | "macrociclo peptidomimético e seus usos" | |
CR9223A (es) | 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen | |
ATE507878T1 (de) | Gerät für intensitätsmodulierte kleinraumbestrahlungstherapie | |
ME01532B (me) | Jedinjenja | |
ATE451892T1 (de) | Gerät zur remodellierung von weichem körpergewebe | |
GT200600092A (es) | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer | |
DE60239931D1 (de) | Kombinationstherapie | |
IL187343A0 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
DK1628685T3 (da) | Antivirale phosphonatanaloge | |
PA8667201A1 (es) | Nuevos compuestos farmaceuticos | |
GT200600430A (es) | Compuestos de carboxiamina y metodos de uso de los mismos | |
UY30094A1 (es) | Compuestos químicos | |
ECSP055967A (es) | N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
ECSP056201A (es) | Triazolopirimidinas | |
ECSP056247A (es) | Triazolopirimidinas | |
HN2010000330A (es) | DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION | |
UY29417A1 (es) | Agentes endoparasiticidas | |
SE0301650D0 (sv) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |